# generic drugs

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/generic-drugs-product
Canonical HTML page: https://getbiobrief.com/entity/generic-drugs-product

## Timeline

- **2029-08-01**: Tariff Escalates to 200% — The tariff rate doubles to 200% on generic drug imports.
- **2028-08-01**: 100% Tariff Takes Effect — A 100% duty is imposed on eligible generic drug imports.
- **2026-08-01**: Duty‑Free Period Begins — Imported generics enter a two‑year duty‑free window.
- **2026-07-21**: Generic Drug Tariff Schedule Announced — The President announces that generic drugs will remain duty‑free for two years, then face 100% (2028) and 200% (2029) tariffs under Section 232.
- **2026-04-02**: Executive Order Tariffs Patented Medicines — President Trump signs an order imposing 100% tariffs on imported patented drugs while exempting generics, biosimilars, and their ingredients.

## Recent coverage (2 stories)

### Biosimilars Hit by Tariffs: 200% Duty by 2029 Threatens Biotech Outsourcing Models
2026-08-07 06:30:09 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

The tariff escalation to 200% on generic drugs by August 2029 also applies to biosimilars, which were initially exempt. For biotech and pharma, this could disrupt outsourcing strategies and market access for follow-on biologics. The timeline analysis details product-level risks.
Full story: https://getbiobrief.com/story/biotech-pharma-generic-drug-tariffs-biosimilars

### 200% US Tariff Threatens Indian Pharma's $50B+ US Generic Business
2026-08-01 11:15:43 · Sentiment: Negative · Impact: 6/10 · Sources: 2

The proposed US tariff on generic drugs—jumping to 200%—poses an existential threat to Indian pharmaceutical companies that have long dominated the American market. With margins razor-thin and a 4-5 year timeline needed to onshore production, industry leaders call the plan 'completely out of scope,' potentially forcing a major restructuring of global generic supply chains.
Full story: https://getbiobrief.com/story/indian-pharma-us-generic-tariff-200-percent-existential-threat

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.